• 1
    Chobanian AV, Bakris GL, Black HR, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report. Hypertension. 2003;42:12061252.
  • 2
    National Clinical Guideline Centre. Hypertension. Clinical Management of Primary Hypertension in Adults. London, UK:National Institute for Health and Clinical Excellence (NICE); 2011. 36 (Clinical guideline; no. 127).
  • 3
    Daskalopoulou SS, Khan NA, Quinn RR, et al. The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol. 2012;28:27.
  • 4
    NCQA. Quality Compass® 2012. Available at: (Accessed June 18, 2013).
  • 5
    Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension. A cluster randomized, controlled trial. Hypertension. 2009;53:646653.
  • 6
    Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4:4250.
  • 7
    Makani H, Bangalore S, Romero J, et al. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med. 2011;124:128135.
  • 8
    Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:24172428.
  • 9
    Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366372.
  • 10
    Jamerson KA, Bakris GL, Weber MA. 24-hour ambulatory blood pressure in the ACCOMPLISH trial. N Engl J Med. 2010;363:98.
  • 11
    Yeh RW, Sidney S, Chandra MBA, et al. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010;362:21552165.
  • 12
    Sidney S, Jaffe M, Nguyen-Huynh MN, et al. Closing the gap between cardiovascular and cancer mortality in an integrated health care delivery system, 2000–2008: the Kaiser Permanente experience. Circulation. 2008;124:21S; A13610.
  • 13
    National Kidney Foundation. KDOQI clinical practice guidelines on hypertension antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(Suppl 1):S1S290.
  • 14
    Fox CH, Swanson A, Kahn LS, et al. Improving chronic kidney disease care in primary care practices: an upstate New York practice-based research network (UNYNET) study. J Am Board Fam Med. 2008;21:522530.
  • 15
    Jafar TH. Systemic hypertension and nondiabetic chronic kidney disease: the best evidence-based therapeutic approach today. Eur Rev Med Pharmacol Sci. 2005;9:112.
  • 16
    American Diabetes Association. Standards of medical care in diabetes 2013. Diabetes Care. 2013;36(Suppl 1):S11S66.
  • 17
    KDOQI clinical practice guidelines clinical practice recommendations for diabetes chronic kidney disease. Am J Kidney Dis. 2007;49(Suppl 2):S12S154.
  • 18
    Franklin SS, Neutel JM. Initial combination therapy for rapid and effective control of moderate and severe hypertension. J Hum Hypertens. 2009;23:411.
  • 19
    Maddox TM, Ross C, Tavel HM, et al. BP trajectories and associations with treatment intensification, medication adherence, and outcomes among newly diagnosed CAD patients. Circ Cardiovasc Qual Outcomes. 2010;3:347357.
  • 20
    Wright JT, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005;293:15951608.
  • 21
    Flack JM, Sica DA, Bakris G, et al. Management of high blood pressure in blacks. An update of the International Society on Hypertension in Blacks Consensus Statement. Hypertension. 2010;56:780800.
  • 22
    Veterans Administration Co-operative Study Group on Antihypertensive Agents. Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide. Br J Clin Pharmacol. 1982;14:97S101S.
  • 23
    Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839845.
  • 24
    Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association professional education committee of the council for high blood pressure research. Hypertension. 2008;51:14031419.
  • 25
    Marrs JC. Spironolactone management of resistant hypertension. Ann Pharmacother. 2010;44:17621768.
  • 26
    Handler J. Overlapping spironolactone dosing in primary aldosteronism and resistant essential hypertension. J Clin Hypertens (Greenwich). 2012;14:732734.
  • 27
    Fujii H, Nakahama H, Yoshihara F, et al. Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone. Kobe J Med Sci. 2005;51:16.
  • 28
    Hermida RC, Ayala DE, Mojon A, Fernandez JR. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int. 2010;27:16291651.
  • 29
    Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18:527539.
  • 30
    Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically complied dosing histories. BMJ. 2008;336:11141117.